Skip Navigation


Mutagenesis Advance Access originally published online on November 15, 2005
Mutagenesis 2005 20(6):449-454; doi:10.1093/mutage/gei062
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Material
Right arrow All Versions of this Article:
20/6/449    most recent
gei062v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Van Gompel, J.
Right arrow Articles by Walmsley, R.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Gompel, J.
Right arrow Articles by Walmsley, R.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author 2005. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

An assessment of the utility of the yeast GreenScreen assay in pharmaceutical screening

J. Van Gompel2, F. Woestenborghs2, D. Beerens2, C. Mackie2, P.A. Cahill1, A.W. Knight1, N. Billinton1, D.J. Tweats3 and R.M. Walmsley1,*

1Faculty of Life Sciences, University of Manchester, Jackson's Mill, Manchester M60 1QD, UK, 2Johnson&Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, Department of ADME/TOX, B-2340 Beerse, Belgium and 3Genetics Department, University of Wales Swansea, Singleton Park, Swansea SA2 8PP, UK

In this paper we describe an initial reproducibility study of 12 proprietary compounds followed by the assessment of 51 marketed pharmaceuticals and, lastly, a summary of the data so far from 2698 proprietary compounds from the Johnson & Johnson (J&J) compound library, in the yeast GreenScreen® assay (GSA). In this assay, a reporter system in the yeast cells employs the DNA damage inducible promoter of the RAD54 gene, fused to the extremely stable green fluorescent protein (GFP). The assay proved to be very robust, the Excel templates provided by Gentronix with the assay interfaced well with in-house J&J systems with little adaptation, the assay was very rapid to perform and used very little compound. The results confirm previous work which suggests that the yeast GSA detects different classes of genotoxic compounds to the Ames assay and as a result can help screen out important genotoxic compounds at the pre-regulatory test phase that are missed by Ames-test-based screens alone. A combination of SAR evaluation of genotoxicity plus an Ames-test-based screen and the GSA provides a powerful pre-regulatory test battery to aid in the selection of successful drug candidates.

* To whom correspondence should be addressed. Tel: +44 161 306 4174; Fax: +44 161 236 0409; Email: richard.walmsley{at}manchester.ac.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Biomol ScreenHome page
A. W. Knight, L. Birrell, and R. M. Walmsley
Development and Validation of a Higher Throughput Screening Approach to Genotoxicity Testing Using the GADD45a-GFP GreenScreen HC Assay
J Biomol Screen, January 1, 2009; 14(1): 16 - 30.
[Abstract] [PDF]

Home page
 MutagenesisHome page
A. W. Knight, N. Billinton, P. A. Cahill, A. Scott, J. S. Harvey, K. J. Roberts, D. J. Tweats, P. O. Keenan, and R. M. Walmsley
An analysis of results from 305 compounds tested with the yeast RAD54-GFP genotoxicity assay (GreenScreen GC) including relative predictivity of regulatory tests and rodent carcinogenesis and performance with autofluorescent and coloured compounds
Mutagenesis, November 1, 2007; 22(6): 409 - 416.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
D. Jacobson-Kram and J. F. Contrera
Genetic Toxicity Assessment: Employing the Best Science for Human Safety Evaluation Part I: Early Screening for Potential Human Mutagens
Toxicol. Sci., March 1, 2007; 96(1): 16 - 20.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.